Should we aim at tissue renin-angiotensin systems?

Pharmacy World and Science

Volumn 20, Issue 3, 1998, Pages 93-99

  Smits, Jos F M ^a   Passier, Robert C J J ^a   Daemen, Mat J A P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ACE inhibitors; Angiotensin sysystems; Angiotensins; Biologic actions; Biosynthesis; Receptors; Review; Tissue renin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; QUINAPRIL;

BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DNA POLYMORPHISM; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG THERAPY; GENETIC VARIABILITY; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031921376     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008621913932     Document Type: Review

References (85)

1. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. Drugs 1995;49:516-35.
2. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992;10(Suppl. 7):S13-26.
3. Boucher R, Asselin JH, Genest J. A new enzyme leading to direct formation of angiotensin II. Cire Res 1974;34(Suppl. 1):I203-9.
4. Wintroub B, Klickstein LB, Dzau VJ, Watt KWK. Granulocyte-angiotensin system: identification of angiotensinogen as substrate of leucocyte cathepsin G. Biochemistry 1984;23:227-32.
5. Tang SS, Loscalzo J, Dzau VJ. Tissue plasminogen activator actvates renin angiotensin in vitro. J Vasc Med Biol 1989;1:67-74.
6. Boer PH, Ruzicka M, Lear W, Harmsen E, Rosenthal J, Leenen FH. Stretch-mediated activation of cardiac renin gene. Am J Physiol 1994;267:H1630-1636.
7. Dzau VJ, Sasamura H, Hein L. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. J Hypertens 1993;11(Suppl. 3):S13-8.
8. Urata H, Healey B, Stewart RW, Bumpus FM, Hussain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
9. Urata H, Strobel F, Ganten D. Widerspread tissue distribution of human chymase. J Hypertens 1994;12(Suppl. 9):S17-22.
10. Moriguchi A, Tallant A, Matsumura K, et al. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 1995;25:1260-5.
11. Abdelrahman A, Pang CCY. Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan. Can J Physiol Pharmacol 1992;70:716-19.
12. Brown NJ, Vaughan DE. The renin-angiotensin and fibrinolytic systems. Co-conspirators in the pathogenesis of ischemic cardiovascular disease. Trends Cardiovasc Med 1996;6:239-43.
13. Goodfriend TL. Angiotensins: a family that grows from within. Hypertension 1991;17:139-40.
14. Douglas JG. Angiotensin II receptor subtypes of the kidney cortex. Am J Physiol 1987;253:F1-7.
15. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors. Hypertension 1991;17:720-3.
16. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991;351:233-6.
17. Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991;351:230-2.
18. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.
19. Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phophotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-6.
20. Inagami T, Mizukoshi M, Guo D-F. Angiotesnin II receptor: molecular cloning, functions and regulation. In: Saavedra JM and Timmermans PBMWM, eds. Angiotesnin receptors. New York: Plenum Press, 1994:1-17.
21. Inagami T, Guo D-F, Kitami Y. Molecular biology of angiotensin II receptors: an overview. J Hypertens 1994;12(Suppl. 10):83-94.
22. Zhang J, Pratt RE. The AT-2 receptor selectively associates with G-iα2 and G-iα3 in the rat fetus. J Biol Chem 1996;271:15026-33.
23. Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, De Gasparo M. The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Comm 1992;1:206-11.
24. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT-2) receptor antagonizes the growth effects of the AT-1 receptopr: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92:10663-7.
25. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 1996;28:916-18.
26. Ji H, Sandberg K, Khang Y, Catt KJ. Molecular cloning, sequencing and functional expression of an amphibian angiotensin II receptor. Biochem Biophys Res Comm 1993;194:756-62.
27. Sandberg K, Ji H, Clark AJL, Shapira H, Catt KJ. Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem 1992;267:9455-8.
28. Murphy TJ, Nakamura Y, Takeuchi K, Alexander RW. A cloned angiotensin receptor isoform from the turkey adrenal gland is pharmacologically distinct from mammalian angiotensin receptors. Mol Pharmacol 1993;44:1-7.
29. LeNoble FAC, Schreurs NHJS, Van Straaten HWM, et al. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 1993;264:R460-5.
30. Ahmed A, Li XF, Shams M, et al. Localization of the angiotensin II and its receptor subtype expression in human endometrium and identification of a novel high-affinity angiotensin II binding site. JClinInvest 1995;96:848-57.
31. Neuss M, Regitz-Zagrosek V, Hildebrandt A, Fleck E. Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation. Biochem Biophys Res Comm 1994;204:1334-9.
32. Hanesworth JM, Sardinia MF, Krebs LT, Hall KL, Harding JW. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J Pharmacol Exp Ther 1993;266:1036-42.
33. Hall KL, Venkateswaran S, Hanesworth JM, Schelling ME, Harding JW. Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. Regul Pept 1995;58:107-15.
34. Regitz-Zagrosek V, Friedel N, Heymann A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995;91:1461-71.
35. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:206-51.
36. Meggs LG, Coupet J, Huang H, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993;72:1149-62.
37. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993;73:439-47.
38. de Gasparo M, Rogg H, Brink M, et al. Angiotensin II receptor subtypes and cardiac function. Europ Heart J 1994;15(Suppl. D):98-103.
39. Rogg H, de Gasparo M, Graedel E, et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Europ Heart J 1996;17:1112-20.
40. Neyses L, Nouskas J, Luyken J, et al. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult cardiomyocytes. J Hypertens 1993;11:927-34.
41. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II induced cardiomyocyte hypertrophy. Hypertension 1996;28:635-40.
42. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993;72:1245-54.
43. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-Stimulated Protein Synthesis in Cultured Vascular Smooth Muscle Cells. Hypertension 1989;13:305-14.
44. Bunkenburg B, van Amelsvoort T, Rogg H, Wood JM. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992;20:746-5.
45. Holycross BJ, Peach MJ, Owens GK. Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro. J Vasc Res 1993;30:80-6.
46. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK. Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996;27:897-905.
47. Stoll M, Meffert S, Stroth U, Unger T. Growth or antigrowth: angiotensin and the endothelium. J Hypertens 1995; 13:1529-34.
48. Bernstein KE, Marrero MB. The importance of tyrosine phosphorylation in angiotensin II signaling. Trends Cardiovasc Med 1996;6:179-87.
49. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
50. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new trend? Circulation 1996;94:240-3.
51. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiomyocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95.
52. Pollman M, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996;79:748-56.
53. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996;93:156-60.
54. Tanaka M, Ohnishi J, Ozawa Y, et al. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Comm 1995;207:593-8.
55. Danser AHJ, Koning MMG, Admiraal PJJ, Derkx FH, Verdouw PD, Schalekamp M. Metabolism of angiotensin I by different tissues in the intact animal. Am J Physiol 1992;263:H418-2.
56. Admiraal PJJ, Danser AHJ, Jong MS, Pieterman H, Derkx FHM, Schalekamp M. Regional angiotensin II production in essential hypertension and renal artery stenosis. Hypertension 1993;21:173-8.
57. Campbell DJ. The site of angiotensin production. J Hypert 1985;2:199-207.
58. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1986;79:1-6.
59. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
60. Hokimoto S, Yasue H, Fujimoyo K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996;84:1513-8.
61. Paul M, Stock P, Langheinrich M, Liefeldt L, Schonfelder G, Bohm M. Role of the cardiac renin-angiotensin system in human heart failure. Adv Exp Biol 1995;377:279-83.
62. Passier RC, Smits JF, Verluyten MJ, Studer R, Drexler H, Daemen MJ. Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 1995;269:H1268-76.
63. Danser AHJ, Admiraal PJJ, Derkx FHM, et al. Cardiac renin is kindney-derived. J Hypertens 1993;11(Suppl. 5):S224-5.
64. Passier RCJJ, Smits JFM, Verluyten MJA, Daemen MJAP. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol 1996;271:H1040-8.
65. Iwai N, Izumi M, Inagami T, Kinoshita M. Induction of renin in medial smooth muscle cells by balloon injury. Hypertension 1997;29:1044-50.
66. Passier RCJ, Verluyten MJA, Daemen MJAP, Smits JFM. Regulation of angiotensinogen and renin mRNA expression in different tissues of the rat. In: McGregor GA, Sever PS, eds. Current Advances in ACE-inhibition. v. 3. London: Churchill Livingstone, 1993:150-4.
67. Doria A, Onuma T, Gearin G, Freire MBS, Warram JH, Krolewski AS. Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension 1996;27:1134-9.
68. Castellano M, Muiesan ML, Beschi M, et al. Angiotensin II type 1 receptor A/C-1166 polymorphism. Relationships with blood pressure and cardiovascular structure. Hypertension 1996;28:1076-80.
69. Lachurié M-L, Azizi M, Guyene T-T, Alhenc-Gelas F, Ménard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995;91:2933-42.
70. Schmidt S, van Hooft IMS, Grobbee DE, Ganten D, Ritz E. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: dutch hypertension and offspring study. J Hypertens 1993;11:345-8.
71. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
72. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel J-M, Ward RH. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995;91:2120-4.
73. Kauma H, Päivänsalo M, Savolainen MJ, et al. Association between angiotensin converting enzyme gene polymorphism and carotid atherosclerosis. J Hypertens 1996;14:1183-7.
74. McLaughlin KJ, Harden PN, Ueda S, Boulton-Jones JM, Connell JMC, Jardine AG. The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension 1996;28:912-5.
75. Panahloo A, Andrès C, Mohamed-Ali V, et al. The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance? Circulation 1995;92:3390-3.
76. Unger T, Ganten D, Lang RE, Scolkens BA. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1986;6:872-80.
77. Strauer BE. Regression of myocardial and coronary hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 1988;12(Suppl.4):45-54.
78. Dahlöf B, Pennert K, Hansson L. Regression of left ventricular hypertrophy - A meta-analysis. Clin Exp Hypert 1992;A14:173-8.
79. Ruzicka M, Skarda V, Leenen FHH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568-73.
80. Ruzicka M, Leenen FHH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 1995;91:16-9.
81. Powell JS, Muller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990;16(Suppl. 4):S42-9.
82. Clozel J-P, Powell JS, Kuhn H, Müller RKM, Hefti F, Baumgartner R. Vascular protection with cilazapril. Drugs 1991;41(Suppl. 1):62-7.
83. MERCATOR study group. Does the new angiotensin-converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992;86:100-10.
84. Lyons D, Webster J, Benjamin N. Effect of enalapril and quinapril on forearm vascular ACE in man. Eur J Clin Pharmacol 1997;51:373-8.
85. Johnston CI, Jandeleit K, Mooser V, et al. Angiotensin converting enzyme and its inhibition in the heart and blood vessels. J Cardiovasc Pharmacol 1992;20(Suppl. B):S6-S11.